|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF432 |
Gene summary for ZNF432 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF432 | Gene ID | 9668 |
| Gene name | zinc finger protein 432 | |
| Gene Alias | ZNF432 | |
| Cytomap | 19q13.41 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R4I3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9668 | ZNF432 | HCC1 | Human | Liver | HCC | 1.05e-03 | 1.14e+00 | 0.5336 |
| 9668 | ZNF432 | HCC2 | Human | Liver | HCC | 6.04e-28 | 4.61e+00 | 0.5341 |
| 9668 | ZNF432 | HCC5 | Human | Liver | HCC | 4.41e-11 | 1.37e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF432 | TREG | Lung | AIS | NOA1,BTN3A1,GTF2H3, etc. | 1.00e-01 |  |
| ZNF432 | CD4TN | Lung | AIS | NOA1,BTN3A1,GTF2H3, etc. | 2.01e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF432 | insertion | Frame_Shift_Ins | novel | c.615_616insTTTGGGAGGCTGAGGCAGGCGGATCACTTGAGGTCAGGAGTTTT | p.Val206PhefsTer58 | p.V206Ffs*58 | O94892 | protein_coding | TCGA-AR-A0U3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ZNF432 | deletion | In_Frame_Del | novel | c.406_414delACTTTGAAA | p.Thr136_Lys138del | p.T136_K138del | O94892 | protein_coding | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | ||
| ZNF432 | SNV | Missense_Mutation | c.1267N>G | p.His423Asp | p.H423D | O94892 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF432 | SNV | Missense_Mutation | c.1178N>A | p.Arg393Gln | p.R393Q | O94892 | protein_coding | tolerated(0.06) | probably_damaging(0.991) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF432 | SNV | Missense_Mutation | rs765063035 | c.1278G>T | p.Glu426Asp | p.E426D | O94892 | protein_coding | deleterious(0.04) | benign(0.01) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZNF432 | SNV | Missense_Mutation | rs183925976 | c.758G>T | p.Arg253Ile | p.R253I | O94892 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ZNF432 | SNV | Missense_Mutation | c.590G>T | p.Arg197Ile | p.R197I | O94892 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF432 | SNV | Missense_Mutation | rs376544430 | c.842G>A | p.Arg281Gln | p.R281Q | O94892 | protein_coding | deleterious(0.02) | probably_damaging(0.972) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| ZNF432 | SNV | Missense_Mutation | rs747869577 | c.496C>T | p.Leu166Phe | p.L166F | O94892 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| ZNF432 | SNV | Missense_Mutation | novel | c.15N>T | p.Gln5His | p.Q5H | O94892 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |